Cardiac output improvement by pecavaptan: a novel dual‐acting vasopressin V1a/V2 receptor antagonist in experimental heart failure

Aims Arginine vasopressin (AVP) mediates deleterious effects via vascular V1a and renal V2 receptors in heart failure (HF). Despite positive short‐term decongestive effects in phase II HF studies, selective V2 receptor antagonism has shown no long‐term mortality benefit, potentially related to unopp...

Full description

Bibliographic Details

Published in:	European journal of heart failure Vol. 23; no. 5; pp. 743 - 750
Main Authors:	Mondritzki, Thomas, Mai, Thuy Anh, Vogel, Julia, Pook, Elisabeth, Wasnaire, Pierre, Schmeck, Carsten, Hüser, Jörg, Dinh, Wilfried, Truebel, Hubert, Kolkhof, Peter
Format:	Journal Article
Language:	English
Published:	Oxford, UK John Wiley & Sons, Ltd 01-05-2021
Subjects:	Acute Heart Failure Animal model Heart failure Pecavaptan V1a receptor V2 receptor Vasopressin antagonist
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!